Loading
Lung Cancer Research Studies / Cancer Treatment and Pharmacology / Chemotherapy-induced Cardiotoxicity and Mitigation · Journal article
BMC Cardiovascular Disorders · August 17, 2026
Encouraging direction, but not yet definitive.
This single-centre study documents a high incidence (74.5%) of asymptomatic cancer therapy-related cardiac dysfunction in 98 Indonesian breast cancer patients receiving anthracyclines, detected by hs-Troponin I, global longitudinal strain, and mechanical dispersion monitoring over 6 months. The findings support integration of subclinical biomarkers for early detection but derive from a retrospective cohort without a control arm and are geographically limited.
Single-centre retrospective analytical study with prospective serial cardiac monitoring. 98 breast cancer patients treated with anthracyclines at a top-tier referral hospital in Indonesia; study period July 2018 to February 2020.. Intervention: Anthracycline chemotherapy for breast cancer. n = 98. Single centre in Indonesia.
CTRCD occurred in 74.5% of patients, predominantly asymptomatic (63.26% of cases were mild) Symptomatic CTRCD was 7.14%, whereas asymptomatic dysfunction was detected as early as 1 month post-chemotherapy LVEF declined significantly from 68.2 ± 6.2% to 61.3 ± 8.8% (p < 0.001) over 6 months
No data on long-term clinical outcomes (heart failure hospitalization, mortality) or cardioprotective intervention efficacy
The high frequency of asymptomatic CTRCD detected by biomarkers and strain imaging suggests that clinical monitoring alone is insufficient. Clinicians should consider integrating hs-Troponin I, GLS, and mechanical dispersion into routine cardiac surveillance during and after anthracycline therapy; however, the lack of a control arm and single-centre design limit generalizability beyond the study setting.
A single-centre retrospective study with prospective cardiac monitoring showing a high incidence of asymptomatic cardiotoxicity using contemporary biomarkers and strain imaging, but limited by retrospective design and lack of a control comparator.
As stated by the source record.
Quoted from the source exactly as published.
The high frequency of asymptomatic CTRCD detected by biomarkers and strain imaging suggests that clinical monitoring alone is insufficient. Clinicians should consider integrating hs-Troponin I, GLS, and mechanical dispersion into routine cardiac surveillance during and after anthracycline therapy; however, the lack of a control arm and single-centre design limit generalizability beyond the study setting.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract. Background Anthracyclines remain a cornerstone of breast cancer therapy but carry a significant risk of cancer therapy-related cardiac dysfunction (CTRCD). This study evaluates the incidence of CTRCD in an Indonesian setting using the latest 2022 ESC Cardio-Oncology guidelines, focusing on subclinical markers such as hs-Troponin I, Global Longitudinal Strain (GLS) and Mechanical Dispersion (MD). Methods This retrospective analytical study involved 98 breast cancer patients treated with anthracyclines at a top-tier referral hospital in Indonesia from July 2018 to February 2020. Clinical assessments, hs-Troponin I, and echocardiography (LVEF, GLS, and MD) were performed at baseline, 1, 3, and 6 months. CTRCD was defined per the 2022 ESC criteria. Results CTRCD occurred in 74.5% of patients, predominantly as asymptomatic mild cases (63.26%). While symptomatic CTRCD was relatively low (7.14%), asymptomatic dysfunction was detected as early as one month post-chemotherapy. A significant progressive decline was observed in LVEF (68.2 ± 6.2% to 61.3 ± 8.8%, p < 0.001) and GLS (-19.7 ± 2.9% to -17.1 ± 3.5%, p < 0.001). Notably, mechanical dispersion significantly increased over time (p = 0.029), and median hs-Troponin I surged from 1.6 ng/L to 82.2 ng/L (p < 0.001) by month 6. Conclusion The high incidence of asymptomatic CTRCD underscores the inadequacy of relying on clinical symptoms alone. Integration of hs-troponin, GLS, and mechanical dispersion monitoring is essential for early detection, enabling timely cardioprotective intervention.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.